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Abstract
Introduction: There seems to be increasing evidence that inflammation leads to cancer. For several cancers, an
association with white blood cell (WBC) count has been reported. So far, no studies have been performed for
cancer of the oral cavity and WBC. Therefore, the aim of the present study was to look at whether WBC count can
be used as a prognostic marker for recurrence or metastases for oral cancer.
Material and methods: For 278 patients with oral cancer, the preoperative WBC count was compared with the
clinicopathological information: age, gender, T-status, N-status, recurrence, metastases, follow-up time, and time till
recurrence or metastases appeared.
Results: Out of 278 patients, 48 developed recurrence, 24 second tumors, 46 cervical metastases, and 14 distant
metastases. The mean follow-up time was 35.97 months (range: 12-107 months). Significant Pearson correlation at
the 0.05 level could be found for the T-status (0.046), but not for the N status (0.121). No significant correlation
could be found between WBC count and the development of recurrence or metastases.
Conclusion: In conclusion, our findings demonstrate that elevated WBC count does not seem to be a predictor for
recurrence or for further metastases. Further research is recommended to investigate the WBC count in
precancerous lesions and in HPV positive patients with oral SCC.
Introduction
In 1863, Rudolf Virchow postulated the induction
hypothesis that cancer originates at the site of chronic
inflammation because he observed leukocytes in neo-
plastic tissues [1]. Associations between cancer and
infections have been reported for several viruses, like
human papilloma virus (HPV), human immunodefi-
ciency virus (HIV), and chronic hepatitis B. Increasing
evidence also suggests that inflammation may be linked
to the pathogenesis of cancer like M. Crohn and color-
ectal carcinoma.
Some authors have observed an association between
elevated serum C-reactive protein (CRP) levels and
some cancers, like colorectal [2,3], lung [4] and head
and neck [5,6]. Concerning WBC count as a predictor
for cancer, several studies have been performed [7-9].
The stromal tissues of tumors have a high WBC count,
and the inflammatory cell number and their cytokines
production seem to correlate with tumor severity and
prognosis [10].
For oral cancer, there is apparently no available data
concerning WBC count. Therefore, the aim of the cur-
rent study was to investigate the significance of preo-
perative WBC counts as a parameter for development of
lymph node metastases or recurrence.
Material and methods
Chosen for evaluation were 278 oral squamous cell carci-
noma (SCC) patients (119 female, 159 male), with a
mean age of 62.89 years, who were treated between 1999
and 2008 in the Department of Craniomaxillofacial and
Oral Surgery, University Hospital Zurich. The WBC
count came from a period of 1-5 days prior to surgical
treatment. The following clinicopathological information
was collected before data analysis: age, gender, T-status,
N-status, recurrence, metastases, follow-up time, and
time till recurrence or metastases appeared. The mini-
mum follow-up time was 12 months. Exclusion criteria
consisted of inadequate information and a follow-up time
of less than 12 months.
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of WBC among the study participants: 2.5 - 4.79, 4.8 -
5.69, 5.7 - 6.79, 6.8 - 7.89, 7.9 - 9.99, 10.0 - 15.0 cells/μL.
For statistical analysis SPPS
® 18.0 (SPSS Inc, Chicago, IL)
for the Mac
® was used, including the Pearson chi-
squared test for the univariate analysis between the WBC
count and the clinicopathological factors and crosstables.
Results
Out of the 278 patients, 48 developed recurrence, 24
second tumors (Table 1), 46 cervical metastases, and 14
distant metastases (Table 2). The mean follow-up time
was 35.97 months (range: 12-107 months); the mean
time to event recurrence was 24.31 months (range: 7-84
months); and the mean time to event metastases was
18.27 months (range: 4-71 months) (Figure 1).
The baseline distributions of WBC in regard to recur-
rence and metastases are shown in Figures 2 and 3. Out
of 48 patients with local recurrence, 29 had an elevated
WBC count of 6.8-15.0 cells/μL. From 46 patients with
cervical metastases, 18 were in the elevated WBC count
group, and 8 of 14 had distant metastases (Table 2). Sig-
nificant Pearson correlation at the 0.05 level could be
found for the T-status (0.046), but not for the N status
(0.121). No significant correlation could be found
between WBC count and the development of recurrence
or metastases (Figures 4 and 5 ) .T h i si sa l s os u p p o r t e d
by a Pearson chi-squared test for univariate analysis,
with an asymptomatic significance of 0.450 for recur-
rence and 0.459 for metastases.
Discussion
In order to establish prognostic predictors for oral SCC,
several studies have been performed. The purpose of
our study was to attempt to discover a simple and cost-
effective indicator for oral SCC. Based on the findings of
this study, we concluded that WBC count is not a prog-
nostic factor for recurrence of metastases. White blood
cell count is highly variable because it is responsive to
diverse acute and chronic stimuli. It is elevated by infec-
tion, by stress, and by chronic irritative exposures like
smoking [11]. But due to its nonspecificity, WBC count
can predict risk for multiple diseases besides cancer,
coronary heart disease [12], or stroke [13].
For other cancers outside the head and neck, several
studies have been performed. Grimm et al. (1985) [7]
reported that the WBC count was significantly asso-
ciated with risk of cancer death. And Erlinger et al.
(2004) [14] were able to associate WBC count with total
cancer mortality. Shankar eta l .( 2 0 0 6 )[ 9 ]a l s of o u n d
an association between high WBC count and cancer
mortality.
The evidence seems to be increasing that cellular pro-
liferation in an environment rich in inflammatory cells,
growth factors, and activated stroma is associated with
the DNA damage that can potentiate the growth of can-
cer cells [1]. Non-steroidal, anti-inflammatory drugs
may significantly reduce the risk of developing cancer,
in particular that of the gastrointestinal tract [15].
Though no WBC count studies have been performed
for oral cancer, several studies have been done for CRP:
Gallo et al. (1995) [16]. demonstrated the significance of
CRP and IL-6 with regard to tumor stage in 18 patients;
Jablonska et al. (1997) [6] studied the CRP level, as well
as IL-1b,I L - 6 ,a n dT N F - a serum levels related to clini-
cal stages of the disease in 42 patients; and recently
Khandavilli et al. (2009) [5] found in a study of 60
patients that the CRP level is associated with worse
Table 1 Distribution of WBC count and recurrence
recurrence
no recurrence local recurrence second tumour Total
WBCcount 2.5-4.79 Count 19 5 4 28
% within recurrence 9,2% 10,4% 16,7% 10,1%
4.8-5.69 Count 25 6 2 33
% within recurrence 12,1% 12,5% 8,3% 11,9%
5.7-6.79 Count 47 8 6 61
% within recurrence 22,8% 16,7% 25,0% 21,9%
6.8-7.89 Count 43 9 3 55
% within recurrence 20,9% 18,8% 12,5% 19,8%
7.9-9.99 Count 45 13 7 65
% within recurrence 21,8% 27,1% 29,2% 23,4%
10.00-15.00 Count 27 7 2 36
% within recurrence 13,1% 14,6% 8,3% 12,9%
Total Count 206 48 24 278
% within recurrence 100,0% 100,0% 100,0% 100,0%
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found in the present analysis was for T status and
WBC, and that seems to have no clinical relevance.
In 2009, Ki et al. [17] reported a significant correlation
between the presence of acute mucositis and the CRP
level in 40 patients during radiotherapy for primary lar-
yngo-pharyngeal cancer. Therefore, it would be of inter-
est–not only in mucositis patients, but also in
precancerous lesions that are associated with inflamma-
tion, like erosive lichen–to investigate the relation
between inflammatory markers like CRP and WBC
counts.
Several limitations to this analysis must be considered.
First, a WBC count analysis was performed only once;
multiple measurements would have increased the
precision of the results. Although WBC count is variable
from day to day, a single measurement has been shown
to predict risk of death for specific diseases, including
cancer and cardiovascular disease [18]. Second, data on
potentially confounding factors, such as medicinal use of
aspirin or other NSAID, were unavailable.
Despite the potential limitations, the current study has
several important strengths. First, this is the first study,
to the authors’ knowledge, dealing with the association
of WBC count and oral cancer. Second, a relatively long
follow-up time with a mean of 35.97 months was ana-
lyzed. And third, special attention was paid to second
tumors and distant metastasis in addition to local recur-
rence and local metastases.
Table 2 Distribution of WBC count and metastases
metastases
no metastasis cervical LN metastasis distant metastasis Total
WBCcount 2.5-4.79 Count 20 7 1 28
% within metastases 9,2% 15,2% 7,1% 10,1%
4.8-5.69 Count 22 9 2 33
% within metastases 10,1% 19,6% 14,3% 11,9%
5.7-6.79 Count 46 12 3 61
% within metastases 21,1% 26,1% 21,4% 21,9%
6.8-7.89 Count 47 4 4 55
% within metastases 21,6% 8,7% 28,6% 19,8%
7.9-9.99 Count 54 8 3 65
% within metastases 24,8% 17,4% 21,4% 23,4%
10.00-15.00 Count 29 6 1 36
% within metastases 13,3% 13,0% 7,1% 12,9%
Total Count 218 46 14 278
% within metastases 100,0% 100,0% 100,0% 100,0%
Figure 1 Comparison of time to recurrence and time to
metastasis. Figure 2 Distribution of WBC count and recurrence.
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In conclusion, our findings demonstrate that elevated
WBC count does not seem to be a predictor for recur-
rence or further metastases. Further study is needed to
investigate the WBC count in precancerous lesions and
in HPV positive patients with oral SCC.
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